TY - JOUR
T1 - Single-dose rituximab therapy for refractory idiopathic membranous nephropathy
T2 - A single-center experience
AU - Katsuno, Takayuki
AU - Ozaki, Takenori
AU - Kim, Hangsoo
AU - Kato, Noritoshi
AU - Suzuki, Yasuhiro
AU - Akiyama, Shinichi
AU - Ishimoto, Takuji
AU - Kosugi, Tomoki
AU - Tsuboi, Naotake
AU - Ito, Yasuhiko
AU - Maruyama, Shoichi
N1 - Funding Information:
The authors express our special appreciation to Dr Y. Sato, Dr A. Tanaka, Dr F. Kamiya for their efforts. We also thank excellent technical assistance to N. Asano, Y. Sawa and N. Suzuki. This work was supported by a Grant-in-Aid for Progressive Renal Diseases Research, Research on intractable disease, from the Ministry of Health, Labour and Welfare of Japan.
Publisher Copyright:
© 2017 The Japanese Society of Internal Medicine.
PY - 2017
Y1 - 2017
N2 - To date, a recognized treatment for refractory membranous nephropathy (MN) has not been established. Recently, several reports have indicated the efficacy of rituximab as a novel treatment option. However, only a few published accounts exist of rituximab therapy for idiopathic MN (IMN) in the Asian population. We present the cases of three IMN patients who were treated with single-dose rituximab after they showed no response to conventional therapies, including corticosteroids, cyclosporine, cyclophosphamide, mizoribine, and mycophenolate mofetil. Although one case showed no response, a complete or incomplete remission was achieved in the other two cases. Rituximab may therefore be a beneficial treatment option for IMN.
AB - To date, a recognized treatment for refractory membranous nephropathy (MN) has not been established. Recently, several reports have indicated the efficacy of rituximab as a novel treatment option. However, only a few published accounts exist of rituximab therapy for idiopathic MN (IMN) in the Asian population. We present the cases of three IMN patients who were treated with single-dose rituximab after they showed no response to conventional therapies, including corticosteroids, cyclosporine, cyclophosphamide, mizoribine, and mycophenolate mofetil. Although one case showed no response, a complete or incomplete remission was achieved in the other two cases. Rituximab may therefore be a beneficial treatment option for IMN.
UR - http://www.scopus.com/inward/record.url?scp=85021752469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021752469&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.56.7908
DO - 10.2169/internalmedicine.56.7908
M3 - Article
C2 - 28674357
AN - SCOPUS:85021752469
VL - 56
SP - 1679
EP - 1686
JO - Internal Medicine
JF - Internal Medicine
SN - 0918-2918
IS - 13
ER -